TiGenix Appoints Jean Stephenne Chairman & Russell Greig Member of Board of Directors
(firmenpresse) - LEUVEN, BELGIUM -- (Marketwire) -- 09/20/12 -- TiGenix (EURONEXT BRUSSELS: TIG) announced
today that the Company has appointed JeanStéphenne as independent director
and new chairman of the Company's board of directors, and Russell Greig as
independent director, in replacement of Koenraad Debackere and Mounia
Chaoui-Roulleau, who resigned from the board. Former chairman Willy Duron
will remain an independent board member.
"We are delighted and proud to appoint these seasoned professionals, who
both have an outstanding record in the pharmaceutical industry," said Willy
Duron, former chairman of the Board of Directors. "Their long and broad
experience with all aspects of drug development and building innovative
pharmaceutical and biotechnology companies will be of immense value as
TiGenix enters into a pivotal phase of its growth with the commercial
roll-out of ChondroCelect and the advanced clinical development of its cell
therapy programs. The board would like to express its gratitude to Koenraad
Debackere and Mounia Chaoui-Roulleau for their expert guidance and support
through the years."
Jean Stéphenne
Jean Stéphenne was until recently Member of the Corporate Executive Team of
GlaxoSmithKline (GSK), and Chairman and President of GSK Biologicals in
Wavre, Belgium, which he built into a world leader in vaccines. He
currently serves as Chairman of BESIX, IBA and BioWin, and as Director of
BNP Paribas Fortis, VBO/FEB, Groupe Bruxelles Lambert (GBL), and Vesalius
Biocapital.
Russell G. Greig, PhD
Russell Greig worked at GlaxoSmithKline for nearly three decades, most
recently as President of SR One, GSK's Corporate Venture Group. Prior to
joining SR One, he served as President of GSK's Pharmaceuticals
International from 2003 to 2008 and also on the GSK Corporate Executive
Team. Dr Greig currently serves as Chairman of AM Pharma in the
Netherlands, Isconova AB in Sweden and Syntaxin in the UK, and is a member
of the Scottish Science Advisory Council.
The appointments of JeanStéphenne and Russell Greig are effective
immediately subject to final appointment by the next shareholders' meeting.
About TiGenix
TiGenix NV (Euronext Brussels: TIG) is a leading European cell therapy
company with a marketed product for cartilage repair, ChondroCelect®, and
a strong pipeline with clinical stage allogeneic adult stem cell programs
for the treatment of autoimmune and inflammatory diseases. TiGenix is based
out of Leuven (Belgium) and has operations in Madrid (Spain), and
Sittard-Geleen (the Netherlands). For more information please visit
.
Forward-looking information
This document may contain forward-looking statements and estimates with
respect to the anticipated future performance of TiGenix and the market in
which it operates. Certain of these statements, forecasts and estimates can
be recognised by the use of words such as, without limitation, "believes",
"anticipates", "expects", "intends", "plans", "seeks", "estimates", "may",
"will" and "continue" and similar expressions. They include all matters
that are not historical facts. Such statements, forecasts and estimates are
based on various assumptions and assessments of known and unknown risks,
uncertainties and other factors, which were deemed reasonable when made but
may or may not prove to be correct. Actual events are difficult to predict
and may depend upon factors that are beyond TiGenix' control. Therefore,
actual results, the financial condition, performance or achievements of
TiGenix, or industry results, may turn out to be materially different from
any future results, performance or achievements expressed or implied by
such statements, forecasts and estimates. Given these uncertainties, no
representations are made as to the accuracy or fairness of such
forward-looking statements, forecasts and estimates. Furthermore,
forward-looking statements, forecasts and estimates only speak as of the
date of the publication of this document. TiGenix disclaims any obligation
to update any such
forward-looking statement, forecast or estimates to reflect any change in
TiGenix' expectations with regard thereto, or any change in events,
conditions or circumstances on which any such statement, forecast or
estimate is based, except to the extent required by Belgian law.
For more information:
Eduardo Bravo
Chief Executive Officer
Claudia D'Augusta
Chief Financial Officer
Hans Herklots
Director Investor & Media Relations
+32 16 39 60 97
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 19.09.2012 - 23:41 Uhr
Sprache: Deutsch
News-ID 1152831
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
LEUVEN, BELGIUM
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 149 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"TiGenix Appoints Jean Stephenne Chairman & Russell Greig Member of Board of Directors
"
steht unter der journalistisch-redaktionellen Verantwortung von
Tigenix (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
